Your session is about to expire
← Back to Search
Customized Adherence Enhancement for Adolescents and Young Adults (CAE-AYA) for Bipolar Disorder (IGNITE Trial)
IGNITE Trial Summary
This trial will test a customized adherence enhancement intervention developed by the investigative team to see if it is effective in bipolar disorder adults in a high-risk, high-need group: AYAs with BD who are poorly adherent with prescribed BD medications.
- Bipolar Disorder
IGNITE Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.IGNITE Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How many participants are currently engaged in this research endeavor?
"Affirmative. Clinicaltrials.gov provides evidence that this experiment, which was initially advertised on March 15th 2021, is actively enrolling patients. Specifically, 40 individuals are needed from 2 different medical institutions."
Might I be qualified to partake in this research?
"This trial is looking for 40 adolescents aged between 14 - 21 who have been diagnosed with manic disorder. To be eligible, participants must exhibit inadequate adherence to prescribed medications such as mood stabilizers or antipsychotics, and meet the DSM-5 criteria for bipolar type I or II as evaluated by a SCID-5 assessment. Those under 18 will also need written assent from guardians alongside consent; all applicants should possess English fluency."
Are persons under the age of 80 admissible to participate in this research?
"The criteria for this trial specifies that its participants must be between the ages of 14 and 21. This study contains a total of 35 patients below 18 years old, while those over 65 are represented by 114 individuals."
Are there available slots for individuals to join this experiment?
"As detailed on clinicaltrials.gov, this research project continues to seek out eligible participants; the initial post was dated March 15th 2021 and a recent update occurred October 2nd 2022."
Share this study with friends
Copy Link
Messenger